A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
Twenty-one depressed patients with probable Alzheimer's disease (AD) were randomized to receive a 6-week treatment with clomipramine or placebo in a study with a double-blind crossover design. Main outcome measures were Hamilton Depression, Mini-Mental State (MMSE), and Functional Independence...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_08950172_v8_n3_p270_Petracca |
| Aporte de: |
| id |
todo:paper_08950172_v8_n3_p270_Petracca |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_08950172_v8_n3_p270_Petracca2023-10-03T15:42:20Z A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease Petracca, G. Tesón, A. Chemerinski, E. Leiguarda, R. Starkstein, S.E. clomipramine tricyclic antidepressant agent adult aged Alzheimer disease article clinical article clinical trial confusion constipation controlled clinical trial controlled study crossover procedure depression double blind procedure drug efficacy female functional assessment Hamilton scale headache human male mood nausea oral drug administration priority journal randomized controlled trial sleep disorder stomach pain time treatment outcome tremor vertigo Twenty-one depressed patients with probable Alzheimer's disease (AD) were randomized to receive a 6-week treatment with clomipramine or placebo in a study with a double-blind crossover design. Main outcome measures were Hamilton Depression, Mini-Mental State (MMSE), and Functional Independence Measure (FIM) scores. Mood improved significantly on both clomipramine and placebo, but clomipramine was significantly more effective than placebo during the first 6-week treatment period. Patients started on clomipramine maintained improvement during the washout and placebo periods, whereas patients started on placebo worsened during the washout period. However, patients on clomipramine showed significantly lower MMSE scores overall than patients on placebo. No significant drug effects were found on FIM scores. Clomipramine proved to be a useful treatment of depression in patients with probable AD. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_08950172_v8_n3_p270_Petracca |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
clomipramine tricyclic antidepressant agent adult aged Alzheimer disease article clinical article clinical trial confusion constipation controlled clinical trial controlled study crossover procedure depression double blind procedure drug efficacy female functional assessment Hamilton scale headache human male mood nausea oral drug administration priority journal randomized controlled trial sleep disorder stomach pain time treatment outcome tremor vertigo |
| spellingShingle |
clomipramine tricyclic antidepressant agent adult aged Alzheimer disease article clinical article clinical trial confusion constipation controlled clinical trial controlled study crossover procedure depression double blind procedure drug efficacy female functional assessment Hamilton scale headache human male mood nausea oral drug administration priority journal randomized controlled trial sleep disorder stomach pain time treatment outcome tremor vertigo Petracca, G. Tesón, A. Chemerinski, E. Leiguarda, R. Starkstein, S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease |
| topic_facet |
clomipramine tricyclic antidepressant agent adult aged Alzheimer disease article clinical article clinical trial confusion constipation controlled clinical trial controlled study crossover procedure depression double blind procedure drug efficacy female functional assessment Hamilton scale headache human male mood nausea oral drug administration priority journal randomized controlled trial sleep disorder stomach pain time treatment outcome tremor vertigo |
| description |
Twenty-one depressed patients with probable Alzheimer's disease (AD) were randomized to receive a 6-week treatment with clomipramine or placebo in a study with a double-blind crossover design. Main outcome measures were Hamilton Depression, Mini-Mental State (MMSE), and Functional Independence Measure (FIM) scores. Mood improved significantly on both clomipramine and placebo, but clomipramine was significantly more effective than placebo during the first 6-week treatment period. Patients started on clomipramine maintained improvement during the washout and placebo periods, whereas patients started on placebo worsened during the washout period. However, patients on clomipramine showed significantly lower MMSE scores overall than patients on placebo. No significant drug effects were found on FIM scores. Clomipramine proved to be a useful treatment of depression in patients with probable AD. |
| format |
JOUR |
| author |
Petracca, G. Tesón, A. Chemerinski, E. Leiguarda, R. Starkstein, S.E. |
| author_facet |
Petracca, G. Tesón, A. Chemerinski, E. Leiguarda, R. Starkstein, S.E. |
| author_sort |
Petracca, G. |
| title |
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease |
| title_short |
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease |
| title_full |
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease |
| title_fullStr |
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease |
| title_full_unstemmed |
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease |
| title_sort |
double-blind placebo-controlled study of clomipramine in depressed patients with alzheimer's disease |
| url |
http://hdl.handle.net/20.500.12110/paper_08950172_v8_n3_p270_Petracca |
| work_keys_str_mv |
AT petraccag adoubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT tesona adoubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT chemerinskie adoubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT leiguardar adoubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT starksteinse adoubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT petraccag doubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT tesona doubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT chemerinskie doubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT leiguardar doubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease AT starksteinse doubleblindplacebocontrolledstudyofclomipramineindepressedpatientswithalzheimersdisease |
| _version_ |
1807317280707575808 |